Edition:
United Kingdom

Arena Pharmaceuticals Inc (ARNA.OQ)

ARNA.OQ on NASDAQ Stock Exchange Global Select Market

42.22USD
8:01pm BST
Change (% chg)

$0.64 (+1.54%)
Prev Close
$41.58
Open
$41.57
Day's High
$42.47
Day's Low
$41.37
Volume
64,732
Avg. Vol
190,773
52-wk High
$50.00
52-wk Low
$24.14

Select another date:

Tue, May 8 2018

BRIEF-Arena Pharmaceuticals Reports Q1 Loss Per Share $0.80

* EXPECT TO INITIATE PHASE 3 STUDIES FOR RALINEPAG IN PULMONARY ARTERIAL HYPERTENSION IN SECOND HALF OF 2018

BRIEF-Arena Pharmaceuticals To Release Q1 Financial Results And Provide Corporate Update On Tuesday, May 8

* ARENA PHARMACEUTICALS TO RELEASE FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE ON TUESDAY, MAY 8 Source text for Eikon: Further company coverage:

BRIEF-Arena Pharmaceuticals Announces Pricing Of Public Offering Of Common Stock

* ARENA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Arena Pharmaceuticals To Offer 7.5 Mln Shares Of Its Common Stock In An Underwritten Public Offering

* ARENA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Arena Pharma's bowel disease drug meets study goal, shares surge

Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

UPDATE 1-Arena Pharma's bowel disease drug meets study goal, shares surge

March 19 Arena Pharmaceuticals Inc said on Monday a higher dose of its experimental drug succeeded in improving symptoms associated with ulcerative colitis, a chronic bowel disease, in a mid-stage study, sending its shares up 24 percent.

Select another date: